About The Oralair Development Program
According to World Health Organization (WHO) estimates, 20 to 25% of the world's population suffer from respiratory allergic symptoms (rhinitis and/or asthma). By 2020, 50% of the world's population will be affected by allergy according to the ISAAC study. According to WHO, desensitization is the only treatment that addresses the immunological cause of allergy and modifies the natural course of the disease. Nearly 15 to 20% of these patients suffer from moderate to severe allergic rhinitis and rhinoconjunctivitis, not controlled by their usual medical treatment.
Since 2003, Stallergenes has been running the Oralair program, which addresses these unmet medical needs with EBM-documented, registered allergen tablets that are safe and easy-to-use.
This program consists in the development of tablets for four of the main allergens triggering more than 80% of these allergies: grass pollens, house dust mites, birch pollen and ragweed pollen.
The entire program is in the clinical development stage and is proceeding according to schedule.
Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 20% of its turnover, in gross terms, to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.
In 2008, Stallergenes had a turnover of 170,9 million euros and provided desensitization treatments to more than 500,000 patients.
Stallergenes is listed on Euronext Paris (Compartment B and is part of the sample composing the SBF 120 index.'/>"/>
Copyright©2009 PR Newswire.
All rights reserved